OUR Pipeline

Ongoing projects

We have a diverse pipeline of multi-targeted therapies to make a difference in the lives of patients
Project Code
QD-101

PROJECT CODE

QD-101:


Indication: Advanced PXE with arterial calcifications. (ODD applied)
IP: Market exclusivity
Partners: Ectocalix (NET)
QD-201

PROJECT CODE

QD-201:


Indication: Innovative administration for cancer
IP: Device exclusivity
Partners: Business partner pending
QD-301

PROJECT CODE

QD-301:


Indication: Adyuvant intraocular therapy for retinoblastoma (ODD pending)
IP: Patent & market exclusivity
Partners: Business partner pending
QD-401

PROJECT CODE

QD-401:


Indication: Osteoporosis
IP: Exclusive formulation
Partners: Partnership in progress
Indication
Advanced PXE with arterial calcifications (ODD applied)
Innovative administration for cancer
Adyuvant intraocular
therapy for retinoblastoma (ODD pending)
Osteoporosis
Preclinical
PK on going
Safety going
Phase I
2023
Phase II
2022-2024
Pending
2022-2023
Phase III
2022-2025
Pending
Pending
2024
Market
EU
EU & NA
WW
UK, EU and NA

ODD: Orphan Drug Designation -  

PK: Pharmacokinetics -  

WW: Worldwide -  

EU: Europe -  

NA: North America

Qualix assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date and should not make any decisions based on this information as it is subject to changes and/or updates at any time for any number of reasons (including but not limited to changes in company policies, outcomes of clinical trials, market changes, etc.).

Design on Therapies

Building a therapeutic path
  • Considers that repurposed drugs accelerates translation “from the bench to the bedside”.
  • For many severe or currently intractable conditions shortened developments are essential.
  • Qualix DoT helps solving difficulties and adding value to its development.
Testing a new concept
  • Reusing approved products reduces risks in patients, lowers regulatory requirements by decreasing development costs and increases attractiveness in the project.
  • Collaborative work is the most advantageous way to carry out ideas. We can help for the cooperation.
Confirming clinical evidence
  • The availability of a new indication must be accompanied by affordability for patients and stability for the Health System.
  • The maximum benefit is obtained when the interest of all parties are balanced. Qualix DoT works with well-adjusted proposals.